Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™
April 29 2024 - 8:30AM
Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative
LIBERTY® Endovascular Robotic Surgical System, today reports that
the first phase of the previously announced collaboration with
Corewell Health has been completed, which demonstrated the LIBERTY®
System's technical capabilities and outlines potential future
applications in a range of endovascular interventions. The
objective of the collaboration, which will take place in multiple
phases, is to enable telerobotics between remote centers by
utilizing the LIBERTY System. The agreement with Corewell Health
includes the right to mutually evaluate the LIBERTY System for
remote procedures and it is being led by Ryan Madder, M.D., Section
Chief of Interventional Cardiology and Director of the Cardiac Cath
Lab at Corewell Health in Grand Rapids, Michigan.
Dr. Madder and colleagues have
recently published an abstract reflecting the results of the first
phase of the aforementioned collaboration in the Journal of the
American College of Cardiology: Cardiovascular Interventions,
highlighting the Technical Success of Coronary Guidewire and Stent
Delivery Using a Novel Miniaturized Robotic System in a
Pre-Clinical Study.
About Microbot MedicalMicrobot Medical Inc.
(NASDAQ: MBOT) is a pre-clinical medical device company that
specializes in transformational micro-robotic technologies, with
the goals of improving clinical outcomes for patients and
increasing accessibility through the natural and artificial lumens
within the human body.
The LIBERTY® Endovascular Robotic Surgical System aims to
improve the way surgical robotics are being used in endovascular
procedures today, by eliminating the need for large, cumbersome,
and expensive capital equipment, while reducing radiation exposure
and physician strain. The Company believes the LIBERTY®
Endovascular Robotic Surgical System’s remote operation has the
potential to be the first system to democratize endovascular
interventional procedures.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions,
risks inherent in the development and/or commercialization of the
LIBERTY® Endovascular Robotic Surgical System, the outcome of its
studies to evaluate the LIBERTY® Endovascular Robotic Surgical
System, uncertainty in the results of pre-clinical and clinical
trials or regulatory pathways and regulatory approvals, including
whether the Company succeeds in obtaining FDA approval to commence
its pivotal study in humans, any failure or inability to recruit
physicians and clinicians to serve as primary investigators to
conduct regulatory studies which could adversely affect or delay
such studies, , disruptions resulting from new and ongoing
hostilities between Israel and the Palestinians and other
neighboring countries, any lingering uncertainty resulting from the
COVID-19 pandemic, need and ability to obtain future capital, and
maintenance of intellectual property rights. Additional information
on risks facing Microbot Medical can be found under the heading
“Risk Factors” in Microbot Medical’s periodic reports filed with
the Securities and Exchange Commission (SEC), which are available
on the SEC’s web site at www.sec.gov. Microbot Medical disclaims
any intent or obligation to update these forward-looking
statements, except as required by law.
Investor Contact:
Michal Efraty+972-(0)52-3044404IR@microbotmedical.com
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From May 2024 to Jun 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Jun 2023 to Jun 2024